These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Possible association of p53 overexpression and mutation with high-grade chondrosarcoma. Dobashi Y; Sugimura H; Sato A; Hirabayashi T; Kanda H; Kitagawa T; Kawaguchi N; Imamura T; Machinami R Diagn Mol Pathol; 1993 Dec; 2(4):257-63. PubMed ID: 8118603 [TBL] [Abstract][Full Text] [Related]
3. Overexpression of p53 protein in squamous cell carcinomas of head and neck without apparent gene mutations. Xu L; Chen YT; Huvos AG; Zlotolow IM; Rettig WJ; Old LJ; Garin-Chesa P Diagn Mol Pathol; 1994 Jun; 3(2):83-92. PubMed ID: 8061893 [TBL] [Abstract][Full Text] [Related]
4. Correlation between p53 immunostaining patterns and gene sequence mutations in breast carcinoma. Visscher DW; Sarkar FH; Shimoyama RK; Crissman JD Diagn Mol Pathol; 1996 Sep; 5(3):187-93. PubMed ID: 8866232 [TBL] [Abstract][Full Text] [Related]
5. Overexpression of p53 and absent genetic mutation in clear cell chondrosarcoma. Park YK; Park HR; Chi SG; Ushigome S; Unni KK Int J Oncol; 2001 Aug; 19(2):353-7. PubMed ID: 11445851 [TBL] [Abstract][Full Text] [Related]
6. p53 expression and its relationship to DNA alterations in bone and soft tissue sarcomas. Wadayama B; Toguchida J; Yamaguchi T; Sasaki MS; Yamamuro T Br J Cancer; 1993 Dec; 68(6):1134-9. PubMed ID: 8260365 [TBL] [Abstract][Full Text] [Related]
7. Overexpression of p53 and rare genetic mutation in mesenchymal chondrosarcoma. Park YK; Park HR; Chi SG; Kim CJ; Sohn KR; Koh JS; Kim CW; Yang WI; Ro JY; Ahn KW; Joo M; Kim YW; Lee J; Yang MH; Unni KK Oncol Rep; 2000; 7(5):1041-7. PubMed ID: 10948336 [TBL] [Abstract][Full Text] [Related]
8. Altered p53 is associated with aggressive behavior of chondrosarcoma: a long term follow-up study. Oshiro Y; Chaturvedi V; Hayden D; Nazeer T; Johnson M; Johnston DA; Ordóñez NG; Ayala AG; Czerniak B Cancer; 1998 Dec; 83(11):2324-34. PubMed ID: 9840532 [TBL] [Abstract][Full Text] [Related]
9. Loss of heterozygosity and DNA ploidy point to a diverging genetic mechanism in the origin of peripheral and central chondrosarcoma. Bovée JV; Cleton-Jansen AM; Kuipers-Dijkshoorn NJ; van den Broek LJ; Taminiau AH; Cornelisse CJ; Hogendoorn PC Genes Chromosomes Cancer; 1999 Nov; 26(3):237-46. PubMed ID: 10502322 [TBL] [Abstract][Full Text] [Related]
10. Mutation of p53 with loss of heterozygosity in the osteosarcomatous component of a dedifferentiated chondrosarcoma. Grote HJ; Schneider-Stock R; Neumann W; Roessner A Virchows Arch; 2000 May; 436(5):494-7. PubMed ID: 10881744 [TBL] [Abstract][Full Text] [Related]
11. Synchronous multifocal bone sarcomas--a case report and molecular pathologic investigation. Walter H; Schneider-Stock R; Mellin W; Günther T; Nebelung W; Roessner A Gen Diagn Pathol; 1995 May; 141(1):67-74. PubMed ID: 8542510 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic utility of IDH1/2 mutations to distinguish dedifferentiated chondrosarcoma from undifferentiated pleomorphic sarcoma of bone. Chen S; Fritchie K; Wei S; Ali N; Curless K; Shen T; Brini AT; Latif F; Sumathi V; Siegal GP; Cheng L Hum Pathol; 2017 Jul; 65():239-246. PubMed ID: 28552826 [TBL] [Abstract][Full Text] [Related]
13. p53 immunoreactivity and single-strand conformational polymorphism analysis often fail to predict p53 mutational status. Tolbert DM; Noffsinger AE; Miller MA; DeVoe GW; Stemmermann GN; Macdonald JS; Fenoglio-Preiser CM Mod Pathol; 1999 Jan; 12(1):54-60. PubMed ID: 9950163 [TBL] [Abstract][Full Text] [Related]
14. Molecular genetic characterization of both components of a dedifferentiated chondrosarcoma, with implications for its histogenesis. Bovée JV; Cleton-Jansen AM; Rosenberg C; Taminiau AH; Cornelisse CJ; Hogendoorn PC J Pathol; 1999 Dec; 189(4):454-62. PubMed ID: 10629543 [TBL] [Abstract][Full Text] [Related]
15. Changes of the p16 gene but not the p53 gene in human chondrosarcoma tissues. Asp J; Sangiorgi L; Inerot SE; Lindahl A; Molendini L; Benassi MS; Picci P Int J Cancer; 2000 Mar; 85(6):782-6. PubMed ID: 10709095 [TBL] [Abstract][Full Text] [Related]
16. p53 alterations in colon tumors: a comparison of SSCP/sequencing and immunohistochemistry. Curtin K; Slattery ML; Holubkov R; Edwards S; Holden JA; Samowitz WS Appl Immunohistochem Mol Morphol; 2004 Dec; 12(4):380-6. PubMed ID: 15536342 [TBL] [Abstract][Full Text] [Related]
17. Analysis of mutant P53 protein in osteosarcomas and other malignant and benign lesions of bone. Ueda Y; Dockhorn-Dworniczak B; Blasius S; Mellin W; Wuisman P; Böcker W; Roessner A J Cancer Res Clin Oncol; 1993; 119(3):172-8. PubMed ID: 8418091 [TBL] [Abstract][Full Text] [Related]
18. Mutations of the p53 gene in human functional adrenal neoplasms. Lin SR; Lee YJ; Tsai JH J Clin Endocrinol Metab; 1994 Feb; 78(2):483-91. PubMed ID: 8106638 [TBL] [Abstract][Full Text] [Related]
19. p53 mutations and expression in ovarian cancers: correlation with overall survival. Wen WH; Reles A; Runnebaum IB; Sullivan-Halley J; Bernstein L; Jones LA; Felix JC; Kreienberg R; el-Naggar A; Press MF Int J Gynecol Pathol; 1999 Jan; 18(1):29-41. PubMed ID: 9891239 [TBL] [Abstract][Full Text] [Related]
20. Ki-ras and p53 mutations in pancreatic ductal adenocarcinoma. Rall CJ; Yan YX; Graeme-Cook F; Beauchamp R; Yandell DW; Povoski SP; Rustgi AK Pancreas; 1996 Jan; 12(1):10-7. PubMed ID: 8927612 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]